Liquidia FY2027 EPS Estimate Raised by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at HC Wainwright lifted their FY2027 earnings estimates for shares of Liquidia in a report issued on Thursday, July 23rd. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $7.12 for the year, up from their prior forecast of $5.94. The consensus estimate for Liquidia’s current full-year earnings is $3.02 per share. HC Wainwright also issued estimates for Liquidia’s FY2028 earnings at $7.77 EPS, FY2029 earnings at $9.29 EPS and FY2030 earnings at $11.12 EPS.

Other equities analysts have also issued reports about the stock. BTIG Research boosted their target price on shares of Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Piper Sandler set a $129.00 price objective on Liquidia in a research report on Friday. Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday, June 5th. Raymond James Financial restated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Finally, Stephens set a $130.00 price target on Liquidia in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.18.

Liquidia Trading Down 2.1%

Shares of LQDA opened at $84.42 on Monday. Liquidia has a 12-month low of $16.82 and a 12-month high of $91.10. The firm has a market capitalization of $7.51 billion, a P/E ratio of 603.04 and a beta of 0.55. The firm has a 50-day moving average price of $71.77 and a 200 day moving average price of $50.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The firm’s revenue for the quarter was up 4187.1% compared to the same quarter last year.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently modified their holdings of the company. TCG Crossover Management LLC purchased a new stake in shares of Liquidia in the 3rd quarter valued at $38,887,000. MPM Bioimpact LLC boosted its holdings in Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the period. Voloridge Investment Management LLC purchased a new position in Liquidia during the 3rd quarter valued at about $12,571,000. Bank of America Corp DE grew its position in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Finally, Invesco Ltd. grew its position in Liquidia by 428.3% in the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after acquiring an additional 341,009 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 318,893 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the sale, the director owned 1,870,042 shares of the company’s stock, valued at $93,932,209.66. The trade was a 14.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Paul B. Manning sold 200,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total value of $12,782,000.00. Following the transaction, the director owned 716,311 shares in the company, valued at $45,779,436.01. This trade represents a 21.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,019,870 shares of company stock worth $129,491,027. Company insiders own 25.60% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).